Subjects with subjective cognitive decline: 18F-Florbetaben Positrón Emission Tomography Study. - Euro-SCD-FBB2

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)0 sites30 target enrollmentDecember 9, 2016

Overview

No summary available.

Registry

who.int

Start Date

December 9, 2016

End Date

TBD

Last Updated

7 years ago

Study Type

Interventional clinical trial of medicinal product

Sponsor

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)

•1\. According to the principal investigator, participants must be committed to participate and complete all study procedures.
•2\. The patient must report a memory problem (in isolation or in combination with complaints in other domains) with concern.
•3\. Age \>/\= 60\*.
•4\. MMSE cutoff for inclusion will be \= 26\.
•5\. CDR\<0\.5\.
•6\. Has signed the Informed Consent Form voluntarily to participate in the study.
•\* Women of childbearing potential must agree to sexual abstinence, barrier or hormonal contraceptive methods during the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes

•1\. Subjects those are not able to complete the study.
•2\. Any major disease or history of a major disease, especially hepatobilliar disease (AST /ALT \= 5 x ULN) or advanced renal insufficiency (creatinine \= 2 x ULN).
•3\. Current or previous history of alcohol abuse or epilepsy.
•4\. Allergic to Florbetaben or any of its constituents.
•5\. Multiple drug allergies and/or previous history of contrast allergy.
•6\. Any disease or history of disease which, in the opinion of the investigator, can cause disturbance of brain function (e.g. vitamin B12 or folic acid deficiency, disturbed thyroid function).
•7\. Evidence for any other neurological or psychiatric disease, eg. parkinsonism, history of stroke or seizure.
•8\. Pregnancy or breast feeding or planned pregnancy during the study period.